Literature DB >> 3114812

Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.

L Gustafson, L Edvinsson, N Dahlgren, B Hagberg, J Risberg, I Rosén, H Fernö.   

Abstract

Ten patients with Alzheimer's disease were treated with intravenous infusion of physostigmine for 2 h. The acute effects on cognitive function, regional cerebral blood flow, and EEG were compared to placebo (isotonic glucose) using a double-blind cross-over design. Physostigmine causes a limited improvement of psychomotor performance and EEG and an increase of blood flow in the most severely affected cortical areas, predominantly in an early phase of Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3114812     DOI： 10.1007/bf02439583

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  27 in total

1.  Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study.

Authors:  A Brun; L Gustafson
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1976-12-31

2.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

3.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

4.  Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.

Authors:  R S Frackowiak; C Pozzilli; N J Legg; G H Du Boulay; J Marshall; G L Lenzi; T Jones
Journal:  Brain       Date:  1981-12       Impact factor: 13.501

5.  Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry.

Authors:  J Risberg
Journal:  Brain Lang       Date:  1980-01       Impact factor: 2.381

6.  EEG effects of physostigmine and choline chloride in humans.

Authors:  A Pfefferbaum; K L Davis; C L Coulter; R C Mohs; J R Tinklenberg; B S Kopell
Journal:  Psychopharmacology (Berl)       Date:  1979-04-25       Impact factor: 4.530

7.  Differential diagnosis of presenile dementia on clinical grounds.

Authors:  L Gustafson; L Nilsson
Journal:  Acta Psychiatr Scand       Date:  1982-03       Impact factor: 6.392

8.  Neocortical cholinergic neurons in elderly people.

Authors:  P White; C R Hiley; M J Goodhardt; L H Carrasco; J P Keet; I E Williams; D M Bowen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

9.  Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

Authors:  K L Davis; R C Mohs
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

10.  Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.

Authors:  J E Christie; A Shering; J Ferguson; A I Glen
Journal:  Br J Psychiatry       Date:  1981-01       Impact factor: 9.319
View more
  15 in total

1.  Memory modulation with peripherally acting cholinergic drugs.

Authors:  D K Rush; K Streit
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

3.  Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory.

Authors:  M L Furey; P Pietrini; J V Haxby; G E Alexander; H C Lee; J VanMeter; C L Grady; U Shetty; S I Rapoport; M B Schapiro; U Freo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 4.  Physostigmine for Alzheimer's disease.

Authors:  F Coelho; J Birks
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 5.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Altered neural cholinergic receptor systems in cocaine-addicted subjects.

Authors:  Bryon Adinoff; Michael D Devous; Mark J Williams; Susan E Best; Thomas S Harris; Abu Minhajuddin; Tanya Zielinski; Munro Cullum
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

7.  A neurochemical approach for studying response to acetylcholine in Alzheimer's disease.

Authors:  J T Alder; I P Chessell; D M Bowen
Journal:  Neurochem Res       Date:  1995-07       Impact factor: 3.996

Review 8.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

9.  Pharmacokinetics of physostigmine in man following a single application of a transdermal system.

Authors:  K Walter; M Müller; M F Barkworth; A V Nieciecki; F Stanislaus
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

10.  A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease.

Authors:  J T O'Brien; S Eagger; G M Syed; B J Sahakian; R Levy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.